TABLE 2.
Entry | Age 24 mo | Exit | |||||||
---|---|---|---|---|---|---|---|---|---|
HU | Placebo | P | HU | Placebo | P | HU | Placebo | P | |
Number of participants | 91 | 88 | 74 | 72 | 86 | 86 | |||
Lymphocytes/mm3a | 6776 (0.67) | 7106 (0.67) | .494 | 5218 (0.66) | 6550 (0.68) | .003 | 4386 (0.67) | 5219 (0.67) | .012 |
CD3 %b | 53 (11) | 54 (12) | .936 | 56 (10) | 51 (11) | .016 | 55 (10) | 52 (11) | .064 |
CD3 #a | 3527 (0.67) | 3739 (0.66) | .394 | 2859 (0.65) | 3288 (0.66) | .040 | 2384 (0.67) | 2670 (0.67) | .096 |
CD4 %b | 36 (10) | 36 (10) | .856 | 34 (8) | 33 (9) | .185 | 32 (8) | 32 (9) | .653 |
CD4 #a | 2357 (0.67) | 2572 (0.67) | .199 | 1770 (0.65) | 2068 (0.66) | .022 | 1365 (0.67) | 1584 (0.67) | .031 |
Naive CD4+CD45RA+ %b | 77 (9) | 78 (8) | .482 | 71 (10) | 70 (10) | .455 | 68 (11) | 66 (11) | .150 |
Naive CD4+CD45RA+ #a | 1795 (0.69) | 1986 (0.69) | .195 | 1249 (0.68) | 1437 (0.69) | .084 | 916 (0.71) | 1022 (0.71) | .199 |
Memory CD4+CD45RO+ %b | 17 (8) | 16 (7) | .595 | 22 (10) | 23 (8) | .513 | 26 (10) | 27 (10) | .212 |
Memory CD4+CD45RO+ #a | 347 (0.73) | 374 (0.75) | .422 | 359 (0.66) | 445 (0.67) | .003 | 324 (0.67) | 409 (0.66) | <.001 |
CD8 %b | 15 (6) | 15 (7) | .950 | 18 (7) | 16 (7) | .112 | 19 (7) | 17 (6) | .070 |
CD8 #a | 978 (0.70) | 1053 (0.73) | .389 | 882 (0.70) | 975 (0.70) | .267 | 782 (0.71) | 847 (0.70) | .334 |
Naive CD8+CD45RA+ %b | 85 (9) | 85 (10) | .922 | 84 (10) | 82 (12) | .309 | 85 (7) | 82 (9) | .026 |
Naive CD8+CD45RA+ #a | 824 (0.70) | 884 (0.73) | .406 | 735 (0.69) | 792 (0.68) | .370 | 661 (0.71) | 691 (0.70) | .590 |
Memory CD8+CD45RO+ %b | 9.00 (8) | 9.40 (8) | .754 | 9.50 (9) | 11 (8) | .417 | 8.80 (6) | 11 (6) | .031 |
Memory CD8+CD45RO+ #a | 66 (0.99) | 76 (0.94) | .336 | 63 (0.99) | 82 (0.98) | .110 | 57 (0.86) | 78 (0.80) | .008 |
HU, hydroxyurea.
Counts are summarized by geometric means (coefficient of variation) and t test to compare log-transformed counts.
Percentages are summarized by treatment means (SD) and t test.